Bu Yin

Dr. Bu Yin has nearly 10 years of experience in life sciences patent application drafting, global portfolio management, and strategic counseling. Dr. Yin frequently counsels on issues relating to patentability, validity, enforceability, freedom-to-operate, design around, and infringement in various settings, including patent litigation, arbitration, and due diligence assessments related to product development and launch, investment, and technology licensing. Dr. Yin also has experience in offensive and defensive proceedings before the U.S. Patent and Trademark Office, such as third-party preissuance submissions, interference, reexaminations, and inter partes reviews.

Dr. Yin counsels clients in a wide range of technology areas, including synthetic biology (e.g., genome editing technologies and genetically modified organisms for disease control and agriculture), next-generation sequencing (e.g., DNA sequencing, RNA sequencing, and protein sequencing), liquid biopsy, therapeutic antibodies, cell therapies (e.g., chimeric antigen receptor (CAR) and T-cell receptor (TCR) therapies), vaccines, gene therapies, stem cells and regenerative medicine, small molecules, high-throughput drug discovery platforms, microfluidic devices, lateral flow technologies, and drug delivery systems.

Dr. Yin earned his J.D., cum laude, from the University of San Diego while working full time as a patent agent at Morrison & Foerster. During law school, he earned a certificate in the Business and Corporate Law concentration, was a member of the San Diego International Law Journal, and received CALI Awards recognizing highest grades in class for Civil Procedure and for Legal Research and Writing.

Prior to becoming a patent agent, Dr. Yin was a Presidential Postdoctoral Fellow at the Novartis Institutes for Biomedical Research, where he developed a high-throughput si/shRNA-based screening to study cancer cell death. Dr. Yin conducted his Ph.D. research in cancer biology and immunology in several labs at the Children’s Hospital of Philadelphia and the Wistar Institute. His research focused on genetics and epigenetics of DNA damage and repair during B-cell and T-cell development, antibody production and immune responses, and tumorigenesis.

Dr. Yin authored more than 16 scientific publications, including many in leading journals such as Nature Immunology, Molecular Cell, Blood, Journal Experimental Medicine, and Journal of Clinical Investigation. For his exceptional research achievements, Dr. Yin was awarded the Saul Winegrad Award for Outstanding Dissertation (University of Pennsylvania), Emphasis in Tumor Immunology Training Grant (Cancer Research Institute), and the Aflac Inc. Scientist-in-training Award (American Association for Cancer Research). Dr. Yin also received training in advanced biotechnology and bioinformatics at Uppsala University, Sweden, and completed various research projects in neurobiology, peptide chemistry, and organic synthesis of viral inhibitors at Tsinghua University, Beijing, China.

Dr. Yin is registered to practice in California and before the U.S. Patent and Trademark Office and is fluent in Mandarin Chinese.